Search research articles
Contact Us
Filters
Showing results (21-30 of 42) with videos related to
Page
of 5
Sort By:
Clinical Pharmacology and Therapeutics
|
October 1, 1992
Pharmacodynamics and tolerability of L-654,066, a steroid 5 alpha-reductase inhibitor, in men
M Depré, C Meeter, A Van Hecken, et al.
The American Journal of Medicine
|
August 1, 1987
Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus
O L Laskin, D M Cederberg, J Mills, et al.
Journal of the American Academy of Dermatology
|
April 1, 1989
Disseminated ecthymatous herpes varicella-zoster virus infection in patients with acquired immunodeficiency syndrome
I H Gilson, J H Barnett, M A Conant, et al.
The American Journal of Medicine
|
July 20, 1982
Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure
H C Krasny, S H Liao, P de Miranda, et al.
The American Journal of Medicine
|
April 1, 1983
Prospective randomized double-blind comparison of moxalactam and tobramycin in treatment of urinary tract infections
J L Abbruzzese, L E Rocco, O L Laskin, et al.
Clinical Pharmacology and Therapeutics
|
November 1, 1981
Disposition of intravenous radioactive acyclovir
P de Miranda, S S Good, O L Laskin, et al.
The American Journal of Medicine
|
July 20, 1982
Metabolic fate of radioactive acyclovir in humans
P de Miranda, S S Good, H C Krasny, et al.
Clinical Pharmacology and Therapeutics
|
May 1, 1982
Acyclovir kinetics in end-stage renal disease
O L Laskin, J A Longstreth, A Whelton, et al.
Clinical Pharmacology and Therapeutics
|
October 1, 1987
Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome
R B Roberts, O L Laskin, J Laurence, et al.
Lancet (London, England)
|
February 20, 1982
Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy
W H Burns, R Saral, G W Santos, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 42) with videos related to
Sort By:
Page
of 5
Clinical Pharmacology and Therapeutics
|
October 1, 1992
Pharmacodynamics and tolerability of L-654,066, a steroid 5 alpha-reductase inhibitor, in men
M Depré, C Meeter, A Van Hecken, et al.
The American Journal of Medicine
|
August 1, 1987
Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus
O L Laskin, D M Cederberg, J Mills, et al.
Journal of the American Academy of Dermatology
|
April 1, 1989
Disseminated ecthymatous herpes varicella-zoster virus infection in patients with acquired immunodeficiency syndrome
I H Gilson, J H Barnett, M A Conant, et al.
The American Journal of Medicine
|
July 20, 1982
Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure
H C Krasny, S H Liao, P de Miranda, et al.
The American Journal of Medicine
|
April 1, 1983
Prospective randomized double-blind comparison of moxalactam and tobramycin in treatment of urinary tract infections
J L Abbruzzese, L E Rocco, O L Laskin, et al.
Clinical Pharmacology and Therapeutics
|
November 1, 1981
Disposition of intravenous radioactive acyclovir
P de Miranda, S S Good, O L Laskin, et al.
The American Journal of Medicine
|
July 20, 1982
Metabolic fate of radioactive acyclovir in humans
P de Miranda, S S Good, H C Krasny, et al.
Clinical Pharmacology and Therapeutics
|
May 1, 1982
Acyclovir kinetics in end-stage renal disease
O L Laskin, J A Longstreth, A Whelton, et al.
Clinical Pharmacology and Therapeutics
|
October 1, 1987
Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome
R B Roberts, O L Laskin, J Laurence, et al.
Lancet (London, England)
|
February 20, 1982
Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy
W H Burns, R Saral, G W Santos, et al.
Page
of 5